Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharma company leveraging artificial intelligence and genomic data to develop precision oncology therapies, announced that its wholly owned subsidiary, Open-Medicine AI (OMAI), will host a live webinar on September 23 at 12:30 p.m. Eastern. The session will present OMAI's business model, development roadmap, and value proposition as a multi-agentic AI platform for end-to-end therapeutic development. Led by Panna Sharma, founder and CEO of Open-Medicine AI, the webinar will cover the platform's architecture, its expansion beyond rare cancers into additional disease categories and therapeutic modalities, and its planned subscription and enterprise licensing business model.
The announcement matters because it highlights how AI is increasingly being applied to drug discovery and development, potentially reducing the time and cost of bringing new therapies to patients. Lantern Pharma's proprietary RADR artificial intelligence and machine-learning platform integrates large-scale genomic and biological data to identify patients most likely to benefit from its therapies and guide biomarker-driven clinical development. The company's pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI. For investors and industry observers, OMAI's planned subscription and enterprise licensing model could represent a new revenue stream and a scalable approach to therapeutic development. If successful, this model could be adopted by other biopharma companies, accelerating innovation across the sector.
To view the full press release, visit https://ibn.fm/U9lmN. The latest news and updates relating to LTRN are available in the company's newsroom at https://ibn.fm/LTRN. Lantern Pharma is a clinical-stage biopharmaceutical company that uses its RADR platform to transform the cost, pace, and precision of oncology drug development.
The webinar is particularly significant as it may provide insights into how OMAI plans to commercialize its AI platform. The platform's multi-agentic architecture is designed to handle end-to-end therapeutic development, from target identification to clinical trial design. Expansion beyond rare cancers into additional disease categories and therapeutic modalities could broaden the platform's applicability and market potential. The subscription and enterprise licensing business model suggests a shift toward software-as-a-service in biopharma, which could offer more predictable revenue compared to traditional drug development. This approach might attract partnerships with larger pharmaceutical companies seeking to enhance their own R&D processes.
BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences, is one of 75+ brands within the Dynamic Brand Portfolio @ IBN. The platform delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics, and diverse industries, including editorial syndication to 5,000+ outlets. It also offers enhanced press release enhancement to ensure maximum impact and social media distribution via IBN to millions of social media followers. With broad reach and a seasoned team of contributing journalists and writers, BioMedWire is uniquely positioned to serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public.
